Heat Stable Rotavirus Vaccine

  • Total vaccine market exceeded $24B in 2013*.
  • 98% of all vaccines require shipment through cold chain**.
  • 75-100% of vaccines experience “temp excursions” during shipment***.
*Vaccines Market Report, Kalorama, 2013
** Biopharma Cold Chain Sourcebook 2010
***Mattias et al, Vaccine (2007)


  • Logistic & capacity constraints can lead to break in the cold chain which can reduce the efficacy or potency of a vaccine.
  • In some cases can lead to toxicity or public safety concerns.
  • GAVI estimates that only 10% of health care facilities in the world’s poorest countries have a reliable electricity supply.

(*Ref: Rational design of heat stable lyophilized rotavirus vaccine formulations (2018). Hum Vaccin Immunother. doi: 10.1080/21645515.2018.1487499)